Image showing the FDA approval logo with text announcing the approval of Adcetris/Brentuximab Vedotin in combination with other drugs for treating relapsed or refractory Large B-cell Lymphoma. A nurse in blue scrubs with a stethoscope is seen in the background, focusing on medical documentation.

FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care?

Date: February 12, 2025 FDA Approves Adcetris Overview The FDA has approved a new combination therapy for adults with relapsed or refractory Large B-cell Lymphoma (LBCL) on February 11, 2025. This therapy combines Brentuximab Vedotin (Adcetris), Lenalidomide, and Rituximab and is intended for patients who have undergone at least two prior systemic therapies and are … Continue reading FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care?

OncologyTube